Medtronic Completes $550M Acquisition of Scientia Vascular to Strengthen Neurovascular Portfolio

Jun 15, 2026 19:31 CST Updated 19:31

Medtronic

Medical Device Manufacturer

Scientia Vascular

Interventional Medical Device Developer

June 15，MedtronicAnnounced the completion of the previously announced$550 millionAcquisitionScientia VascularTransaction,Both parties will integrate inNeurovascularAccess and therapeutic product portfolio in the nursing field, providing physicians and patients with end-to-end solutions from intervention to treatment.

On March 10, this medical technology giant officially announced that it had entered into a definitive agreement toAcquisition of the private medical technology company Scientia Vascular.

Scientia is headquartered in Salt Lake City, Utah, USA, with approximately 310 employees. Its core products includeAristotle guidewire, Plato 17 microcatheter, Socrates 38 aspiration catheteretc. These products utilize patented microfabrication technology to enable faster and more reliable access within complex and tortuous cerebrovascular anatomical structures.

The core logic behind Medtronic's acquisition this time is “Precise Positioning”。

As an early pioneer in the neurovascular intervention market, Medtronic hasLiquid embolic agents, stent retrievers, flow divertersWhile the “therapeutic end” boasts a robust product portfolio, but in"Access Site"(i.e., precise delivery of the guidewire and microcatheter to the lesion site) has significant limitations.Scientia Vascular precisely fills this gap.。

Medtronic’s acquisition of Scientia Vascular’s innovativeMicro-guidewireandMicrocatheterTechnology:

Seamless Integration: SScientia Vascular’s product portfolio will strongly complement Medtronic’s existing neurovascular product line (such as stent retrievers, flow diverters, etc.), creating a more comprehensive “full suite of products.”
Enhanced Efficiency: Smoother and more controllable guidewires and catheters enable physicians to reach lesion sites faster and more reliably, thereby improving procedural efficiency and success rates.

Linnea Burman, Senior Vice President and President of Neurovascular Business at Medtronicstated: “Medtronic is very pleased to acquire Scientia, which will accelerate significant innovation in the field of neurovascular therapy.”This acquisition has enabled Medtronic to possessComprehensive Product Portfolio from Access to Therapy, laying a more solid foundation for the treatment of hemorrhagic stroke and acute ischemic stroke.“Each year, 12 million people worldwide suffer from stroke. We look forward to leveraging our combined strengths to make greater contributions to improving patient outcomes globally.”

Dr. David Fiorella, Director of the Center for Cerebrovascular Disease at Stony Brook University Medical Centerstated, “All neurointerventional procedures are inseparable from microwires and microcatheters.”Scientia’s revolutionary technology makes every procedure technically more convenient, faster, and ultimately safer. It has driven, and will continue to drive, the advancement of neurovascular surgery.”

Amid the intensifying global competition in the interventional stroke market, large medical device companies are continuously strengthening their product portfolios through acquisitions.

January 15,Boston ScientificAnnounced the acquisition of Penumbra, a leading company in the neuro and peripheral intervention fields, for $14.5 billion, marking the first M&A deal exceeding $10 billion in 2026 and the second-largest acquisition in Boston Scientific's history.This transaction marks Boston Scientific’s return to the neurointerventional arena.

February,StrykerCompleted the acquisition of Inari Medical for $4.9 billion, integrating venous thrombectomy solutions into the neurovascular business portfolio.